ライフサイエンスコーパス: pharmacophore

1 st with a sulfonium isostere of the ammonium pharmacophore.

2 ulfoquinoline lead compound with the minimal pharmacophore.

3 AR study using sumanirole (1) as the primary pharmacophore.

4 lic moiety, imidazolidine-4,5-dione, a known pharmacophore.

5 ere truncated in order to identify a minimum pharmacophore.

6 ore as well as in the amine part outside the pharmacophore.

7 ther antimalarial drugs with the artemisinin pharmacophore.

8 ulline, the proposed donor of the functional pharmacophore.

9 ter forms an essential part of the inhibitor pharmacophore.

10 presented here agree well with the proposed pharmacophore.

11 e that contains the hypothesized Arg-Phe-Phe pharmacophore.

12 domimetic HIV-1 inactivators based on the PT pharmacophore.

13 propyl]piperazi ne (1, PB28) was used as the pharmacophore.

14 has furnished a previously unknown antitumor pharmacophore.

15 rotational flexibility of the carboxymethyl pharmacophore.

16 nist and the other receptor by an antagonist pharmacophore.

17 hylbutenolide in addition to the glutarimide pharmacophore.

18 of (+)-1 is derived from the (+)-naltrexone pharmacophore.

19 was developed with a novel sulfonamide core pharmacophore.

20 ll molecules and definition of corresponding pharmacophores.

21 acetylenic moiety that connects the terminal pharmacophores.

22 c ligands would be composed of two identical pharmacophores.

23 th either one or two lysine-ureido-glutamate pharmacophores.

24 or the regioselective synthesis of potential pharmacophores.

25 e pyridone and pyridine amides and their key pharmacophores.

26 agment-binding sites and their corresponding pharmacophores.

27 ived from canonical or atypical dopaminergic pharmacophores.

28 in the synthesis of diversely functionalized pharmacophores.

29 gned as a combination of quinone/cannabinoid pharmacophores.

30 natural products and a number of established pharmacophores.

31 valent bitopic ligands linking two identical pharmacophores.

32 widely applicable tricyclic, photoswitchable pharmacophores.

33 roviding functionalized alicyclic motifs and pharmacophores.

34 accessible chiral compounds, containing the pharmacophore 1,3,4-thiadiazoline nucleus joined by a sp

35 y acid mimetics linked to the bioactivatable pharmacophore, 1-aminobenzotriazole (ABT).

36 screening a focused library of metal-binding pharmacophores, 8-(methylsulfonylamino)quinoline (8-MSQ)

37 Queries are specified in terms of a pharmacophore, a spatial arrangement of the essential fe

38 strategy for coupling orthogonal antibiotic pharmacophores, a surprising tolerance for substantial c

39 ress this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive w

40 e-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold

41 em located outside the ethylenediamine kappa pharmacophore allows the fine-tuning of the pharmacodyna

42 hianidin, thiamethoxam, and thiacloprid) and pharmacophore-altered metabolites (desnitro-imidacloprid

43 eloped in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors.

44 unds that conjugate a sigma (sigma) receptor pharmacophore and a nitric oxide (NO) photodonor.

45 We also identified the pharmacophore and assessed binding efficacy of second-ge

46 ain models, but the lack of knowledge of its pharmacophore and binding site on ASIC3 has impeded deve

47 ractions and/or hydrogen bonding between the pharmacophore and carbon surface.

48 structural diversity permitted by the tunnel pharmacophore and culminated in the identification of py

49 igned to (a) disrupt the promiscuous binding pharmacophore and diminish off-target interactions and (

50 e/bromodomain inhibitors and generate ad hoc pharmacophore and docking models.

51 A pharmacophore and docking-based virtual screening of com

52 that [des-Arg(7)]Dyn A(1-9)-NH2 is a minimum pharmacophore and its modification at the N-terminus lea

53 rather than the pyrazole moiety of the MP-10 pharmacophore and performed in vivo evaluation.

54 oup to interrupt the lipophilic, promiscuous pharmacophore and promote interaction with human nNOS-sp

55 Finally, we developed a pharmacophore and proposed a mechanistic model for how t

56 e ene reaction easily assembles the asmarine pharmacophore and transmits remote stereochemistry to th

57 everal key features of the psychoplastogenic pharmacophore and used this information to develop N,N-d

58 es of dynamic processes inherent to the OPAC pharmacophores and can help augment our understanding of

59 re valuable transformations for synthesis of pharmacophores and chemical building blocks.

60 ing a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted i

61 e. a combination of static three-dimensional pharmacophores and molecular dynamics-based conformation

62 Merging known pharmacophores and systematic exploration of the structu

63 ar stress and cell viability demonstrate key pharmacophores and their physicochemical properties requ

64 ns are extremely useful in providing protein pharmacophores and to characterize function and structur

65 gated phthalazine moieties (antiangiogenetic pharmacophore) and bis(hydroxymethyl)pyrrole moieties (D

66 ere determined to fit a merged sEH/PPARgamma pharmacophore, and structure-activity relationship studi

67 Pockets are represented by pharmacophore-annotated point clouds mimicking ideal lig

68 he 6-hydroxy-1,2,4-triazine-3,5(2H,4H)-dione pharmacophore appears metabolically resistant to O-glucu

69 Through a convergent pharmacophore approach, we synthesized alpha-ketothioami

70 es and to identify which enzyme(s) and which pharmacophores are critical for plasma stability.

71 These independently active pharmacophores are liberated during metabolism, resultin

72 h ASP and AGRP, the hypothesized Arg-Phe-Phe pharmacophores are on exposed beta-hairpin loops.

73 ipids embedding two terminal alkynylcarbinol pharmacophores are reported.

74 Bivalent inhibitors, where two pharmacophores are tethered to a single DFOSq ligand, ha

75 nyl pharmacophore, but not the 7-hydroxy Tic pharmacophore, are better tolerated at kappa and mu rece

76 ide, to establish the tetrahydroisoquinoline pharmacophore as an attractive starting point for lead o

77 s in the arylacetamide and amine part of the pharmacophore as well as in the amine part outside the p

78 their utilization in applications such as in pharmacophores, as scaffolds in molecular construction,

79 tion of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains w

80 eries maintained the potency of the original pharmacophores at both receptors (adenosine A2A and dopa

81 s, appears as a privileged structure for the pharmacophore-based computational strategy.

82 jugating fluorescent dyes to a non-peptidic, pharmacophore-based ligand, based on a molecular modelin

83 We present CSD-CrossMiner, a novel tool for pharmacophore-based searches in crystal structure databa

84 Iterative pharmacophore-based virtual screening was performed to i

85 nformation whereas TAK-779 (with a different pharmacophore) binds to a different high-energy conforma

86 unrelated to the classic phenylethanolamine pharmacophore, binds at the same GluN1/GluN2B dimer inte

87 of types 1-3 consist of three different D2R pharmacophores bound to an affinity-generating lipophili

88 r hand, modifications of the 3-hydroxyphenyl pharmacophore, but not the 7-hydroxy Tic pharmacophore,

89 trongly diminishes the toxicity of the azido pharmacophore, but preserves its antibacterial propertie

90 f those substituents, and secondary aromatic pharmacophores can enhance agonist efficacy for the cAMP

91 The effect is due to azido pharmacophore -CH(2)-CH(OH)-CH(2)-N(3) (for N-(3-azido-2

92 Our work identifies Ile105 as a new pharmacophore component for developing better hCB1R anta

93 This pharmacophore comprises a 6 + 5 fused ring heterocycle l

94 hesis and modification of novel oligopeptide-pharmacophore conjugates by C-H functionalization.

95 ut inferior to Glide for most systems unless pharmacophore constraints are used; in that case rDock a

96 antagonist and identification of the minimum pharmacophore converted the mechanism of inhibition from

97 arbonic anhydrase (CA, EC 4.2.1.1) inhibitor pharmacophores, coupled with either ethylene glycol olig

98 y, this method can be applied to both single-pharmacophore DECLs and self-assembled dual-pharmacophor

99 -pharmacophore DECLs and self-assembled dual-pharmacophore DECLs.

100 lta activator scaffold by rational fusion of pharmacophores derived from selective agonists.

101 strategy starting with SILCS, followed by a pharmacophore-derived X-ray screen and (15)N HSQC NMR ba

102 Using structure-guided pharmacophore design followed by docking, we found two a

103 UmBLs contain one agonist and one antagonist pharmacophore designed to target a melanocortin homodime

104 atural product total synthesis that we term 'pharmacophore-directed retrosynthesis'.

105 udy, based on co-crystallization studies and pharmacophore-docking-based virtual screening, we discov

106 rall neonicotinoid sorption, suggesting that pharmacophore-driven sorption in real waters may be dimi

107 ends attributable to combinations of two key pharmacophore elements within the chemotype.

108 unds containing redox-directed electrophilic pharmacophores employing the Stress & Toxicity PathwayFi

109 Herein, we describe a pharmacophore exploration to identify a highly potent, s

110 cture, which displayed a possible overlay of pharmacophore features supportive for further design of

111 tic scaffold exploration to design a general pharmacophore for AC inhibition.

112 vide information on the structure and on the pharmacophore for ASIC channel inhibition by mambalgins

113 structure similarities revealed a potential pharmacophore for cartilage targeting.

114 chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.

115 amine-based side chain were selected as the pharmacophore for further modification, resulting in met

116 g the position of the carboxylic acid, a key pharmacophore for GPR40.

117 ments that modulate the activity of the core pharmacophore for MC4R and provide a rationale for caref

118 Here, we aimed to generate a new pharmacophore for negative-gating modulation of KCa2/3 c

119 g transcription activation, and identified a pharmacophore for SpCas9 inhibition using structure-acti

120 ne and that the structures revealed a common pharmacophore for the three ligands.

121 ne-gamma-lactam hybrid, which is a potential pharmacophore for the treatment of cancer and Alzheimer'

122 -based C-ring, which possessed the requisite pharmacophores for binding to protein kinase C (PKC) tog

123 ess to important synthetic intermediates and pharmacophores for biologically active molecules.

124 ications about the structural requirement of pharmacophores for further increasing potency and state-

125 ignificant role in providing novel leads and pharmacophores for medicinal chemistry.

126 4-(Pyrimidin-4-yl)morpholines are privileged pharmacophores for PI3K and PIKKs inhibition by virtue o

127 They are also recognized as pharmacophores found in already marketed and well-sold d

128 Herein, the opioid pharmacophore H-Dmt-d-Arg-Aba-beta-Ala-NH2 (7) was linke

129 unds with a 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore have been studied extensively.

130 Endogenous MC4R agonists possess a critical pharmacophore (HFRW), and cyclization of peptide agonist

131 We used a pharmacophore hybridization strategy to combine key stru

132 macophore module to generate natural product-pharmacophore hybrids endowed with unknown biological (p

133 ken together, these results substantiate our pharmacophore hypothesis and validate our ligand-based a

134 A qualitative pharmacophore hypothesis for small molecule ligands at G

135 e-activity relationships (SAR) in the aurone pharmacophore identified heterocyclic variants of the (Z

136 agonists comprising the ethylenediamine KOR pharmacophore in a perhydroquinoxaline scaffold exhibit

137 ranoside scaffold that locks the carboxylate pharmacophore in either the axial or equatorial position

138 xample of how to systematically reengineer a pharmacophore in order to overcome toxicological problem

139 ntrinsic integration of a fluorophore in the pharmacophore in PSMA-targeted small-molecule tracers.

140 onstrated the importance of the di-2-pyridyl pharmacophore in their activity.

141 2,3-Dihydrobenzofurans are key pharmacophores in many natural and synthetic bioactive m

142 cyclopropyldihydrocinnamates to be important pharmacophores in one of our drug discovery programs and

143 nal chemistry and have emerged as privileged pharmacophores in proteasome inhibitors.

144 Enamides represent bioactive pharmacophores in various natural products, and have bec

145 roximately 4 A resolution in the presence of pharmacophores, including a potent antagonist.

146 stics, we hypothesized that the insecticidal pharmacophore influences neonicotinoid sorption.

147 t DEEP-STD NMR can be used to readily obtain pharmacophore information on the protein.

148 positive functional evidence linking tropane pharmacophore interaction with the core substrate-bindin

149 I3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an

150 ains (chi-space) that constitute the peptide pharmacophore is equally important.

151 The aryl sulfamate pharmacophore is highly versatile, operating via three d

152 esis of the highly privileged phenethylamine pharmacophore is reported.

153 preparation of structural variants of known pharmacophores is a key strategy for drug development.

154 stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P.

155 (5-LOX) and soluble epoxide hydrolase (sEH) pharmacophores led to the discovery of a dual 5-LOX/sEH

156 ontain mu opioid agonist and CCR5 antagonist pharmacophores linked through homologous spacers (14-24

157 very of a series of alkylating HDACi using a pharmacophore-linking strategy.

158 The three ligands with a similar pharmacophore (Maraviroc, PF-232798, and Aplaviroc) bind

159 ad compounds identified from a metal-binding pharmacophore (MBP) library screen.

160 computational drug design with metal-binding pharmacophores (MBP).

161 The binding of a series of metal-binding pharmacophores (MBPs) related to the ligand 1-hydroxypyr

162 Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ

163 ations that are represented by metal-binding pharmacophores (MBPs), metalloenzyme structural similari

164 Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 i

165 Despite the conceptual prevalence of pharmacophore methods for scaffold hopping, a variety of

166 Here, we developed a pharmacophore model allowing us to assemble a library of

167 We developed a pharmacophore model and used the putative bioactive conf

168 ranslating essential binding features into a pharmacophore model followed by in silico screening of t

169 ivator and pharmacoenhancer, we have built a pharmacophore model for a CYP3A4-specific inhibitor.

170 ata formed the basis for a three-dimensional pharmacophore model for GHB ligands, which identified mo

171 We developed a pharmacophore model for type II inhibitors that was used

172 entify such a selective binder, we derived a pharmacophore model from the peptide EAVSLKPT, a fragmen

173 This new conorphine KOR agonist class and pharmacophore model provide opportunities for future rat

174 electivity, and stability assays generated a pharmacophore model supporting rational design of highly

175 othesized binding modes and alignment with a pharmacophore model that we have developed.

176 Specifically, we derived a pharmacophore model to describe inhibitors capable of pr

177 We report a pharmacophore model trained on approximately 200 antagon

178 A pharmacophore model was developed and employed to better

179 The pharmacophore model was supported by computational docki

180 from the GSK collection were used to build a pharmacophore model which could be used in the virtual s

181 r further evaluation and optimization of the pharmacophore model.

182 lamp along with structural studies created a pharmacophore model.

183 These results provided the basis to use pharmacophore modeling and molecular docking analyses to

184 tural approach based on docking simulations, pharmacophore modeling and molecular dynamics was applie

185 reening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtu

186 ors (EPIs) library was used for ligand-based pharmacophore modeling studies.

187 ol with combination of similarity search and pharmacophore modeling was applied to virtually screen a

188 g a combination of druggability simulations, pharmacophore modeling, virtual screening, and in vitro

189 By combined pharmacophore-modeling-based in silico and fluorescence

190 enhanced the original method by including a pharmacophore modelling and information of nucleic acid

191 tor classes in light of recent insights from pharmacophore models and cocrystallization studies.

192 The results were in line with the available pharmacophore models and highlighted that the 1,4-dioxan

193 uctural information regarding the utility of pharmacophore models and how selectivity between OX(1) a

194 QSAR models and ligand- and structure-based pharmacophore models and to select the most appropriate

195 In this study, ligand-based pharmacophore models for 17beta-HSD2 inhibitors were con

196 Phe-Tic-(pNO2)DPhe-NH2, revealing new ligand pharmacophore models for melanocortin receptor drug desi

197 n parallel, computational methods can derive pharmacophore models or screen virtual libraries.

198 The pharmacophore models were derived for hydrophobic alpha-

199 Pharmacophore models were developed based on known C3d-l

200 d and reliable, leading to the generation of pharmacophore models with high predictive power.

201 pes of ligands were prepared on the basis of pharmacophore models.

202 transformations: e.g., the installation of a pharmacophore module to generate natural product-pharmac

203 ems would enable access to a series of known pharmacophores (molecular features responsible for a dru

204 screening of large compound databases using pharmacophores, molecular shape and energy minimization.

205 S234 by incorporating generally accepted H3R pharmacophore motifs.

206 ign hinges upon integrating two well-studied pharmacophores, namely, phosphorothioates (pS) and morph

207 r results demonstrate that the neonicotinoid pharmacophore not only confers insecticide selectivity b

208 tified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-deriv

209 A hypothesized, pharmacophore of a natural product is selected as an ear

210 ntains the characteristic tropolone ring and pharmacophore of colchicine(6).

211 ctural elements of the potential therapeutic pharmacophore of ibogaine, and we use this information t

212 as an alkyltriphenylphosphonium moiety to a pharmacophore of interest.

213 s of 35 chemical derivatives, we defined the pharmacophore of LD7, and identified a more potent deriv

214 The pharmacophore of mitoxantrone was further investigated b

215 molecule docking indicated that the tropane pharmacophore of RTI 82 was positioned in the central DA

216 istry effort, we optimized the benzothiazole pharmacophore of SKA-31 toward KCa3.1 selectivity and id

217 with the aim of optimizing the benzothiazole pharmacophore of SKA-31 toward KCa3.1 selectivity.

218 We identified compounds that match the pharmacophore of the key actin residues of Pfn1-actin in

219 n protocol allows direct access to medicinal pharmacophores of broad utility using feedstock substrat

220 cancer cells and provide an overview of the pharmacophores of CDK7 inhibitors, their efficacy in var

221 of dual PARP/PI3K inhibitors that merge the pharmacophores of PARP and PI3K inhibitors.

222 After demonstrating that the pharmacophores of the chelating inhibitors (S)-10a, (R)-

223 The structures indicate a critical pharmacophore on the compounds that leads to the distinc

224 These findings provide insight into a pharmacophore on VSDIV through which modulation of inact

225 Structure-guided addition of a metal-binding pharmacophore onto LE retrofragment scaffolds produced l

226 troduce a broad range of carbonyl-containing pharmacophores onto oligopeptides, thus providing a chem

227 featuring an alpha-hydroxy phenylacetic acid pharmacophore or bioisostere.

228 in-ligand interactions, such as known ligand pharmacophore or interaction sites derived from cosolven

229 leading to displacement of CB7 from included pharmacophores (or from drug loaded porous particles).

230 y their structures to identify the essential pharmacophore, or make functional group changes to impro

231 Many topological pharmacophore patterns are common between natural produc

232 with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP).

233 o ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and

234 Quinolines are common pharmacophores present in numerous FDA-approved pharmace

235 and the natural product piperlongumine as a pharmacophore probe.

236 Our data can instruct on pharmacophore properties to assist the future developmen

237 S) hit followed by truncation to its minimal pharmacophore provided an indazole acid lead compound.

238 Intuitive pharmacophore queries describing, among others, protein-

239 dge Structural Database (CSD) using the same pharmacophore query further emphasizes the flexibility o

240 metal-binding motif of these inhibitors as a pharmacophore rather than a "chelator".

241 urbance, could, in principle, allow for easy pharmacophore recognition when the compounds are aligned

242 n network of interactions that stabilize the pharmacophore region of this class of venom peptides.

243 that resemble the critical two-metal binding pharmacophore required for HIV integrase strand transfer

244 The key structural features of the APN pharmacophore required for substrate recognition were el

245 the results provide further insight into the pharmacophore requirements for allosteric inhibition.

246 ium, suggesting that the combination of both pharmacophores results in synergistic cardioprotective a

247 king docked hits with our library-derived 3D-pharmacophore revealed two distinct asymmetric binding m

248 corresponding sulfones and sulfonamides, two pharmacophores routinely encountered in drug discovery.

249 we characterized the effects of the minimal pharmacophore RWRWRW-NH2.

250 Hits from the pharmacophore screens were docked to C3d and ranked base

251 Hit expansion by two in silico approaches, pharmacophore search followed by docking, and substructu

252 nt-based screening, reporter gene assay, and pharmacophore search were utilized for the small molecul

253 dition of an N-terminal 1-adamantanecarbonyl pharmacophore significantly improved peptidomimetic inhi

254 NTs, whereas desnitro-imidacloprid (positive pharmacophore) sorbed most to COOH-CNTs, indicating the

255 oprid and imidacloprid urea (electronegative pharmacophores) sorbed most extensively to nonfunctional

256 es a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.

257 the primary pharmacophore (PP) and secondary pharmacophore (SP).

258 Fusion of nonopioid pharmacophores, such as neurotensin, with opioid ligands

259 igned mechanisms of action to identify novel pharmacophores supporting Tnks inhibition.

260 Coupling of two distinct pharmacophores, tacrine and trolox, endowed with differe

261 pping agents into agonistic and antagonistic pharmacophores targeting the gastrin-releasing peptide r

262 lts confirm the tryptophan moiety as a solid pharmacophore template for the design of highly potent m

263 gning known active compounds onto identified pharmacophore template.

264 ning procedure, which identified a potential pharmacophore that abrogated HBx RNAi suppression activi

265 This discovery defines a new pharmacophore that displayed selective activity toward a

266 f singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clin

267 P inhibitors based upon a cyclic polysulfide pharmacophore that forms a reversible covalent bond with

268 nderpins a fundamental weakness of the INSTI pharmacophore that is exploited by the virus to engender

269 itiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to ster

270 ur if these models could reveal the fragment pharmacophores that are causally involved in binding.

271 Heterobiaryls are important pharmacophores that are challenging to prepare by tradit

272 back-to-back manuscripts describe the first pharmacophores that favorably and selectively interact w

273 d to generate three-dimensional quantitative pharmacophores that identified hydrophobic regions, H-bo

274 ine heterocycle has been found as the active pharmacophore, the results discussed in this work may pr

275 by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustiv

276 p was introduced to a quinazoline-based PI3K pharmacophore through an appropriate linker.

277 d and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxa

278 ted the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the b

279 fied a sulfonamide scaffold that served as a pharmacophore to generate inhibitors of Mycobacterium tu

280 e appears that Evasin-1 and -4 use different pharmacophores to bind CC chemokines, with the principal

281 ple, that is, molecular probes, carrying two pharmacophores to simultaneously adopt orthosteric and a

282 The teixobactin pharmacophore tolerates ring expansion of the 13-membere

283 The structure shows that potent pharmacophore trans-Ned-19 acts allosterically by clampi

284 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategi

285 Conjugation of two 9-aminoacridine pharmacophores, using linkers of varying length, increas

286 the recently uncovered (S)-dialkynylcarbinol pharmacophore were secured using Carreira's procedure ad

287 molecules in which the primary and secondary pharmacophores were derived from the D3R-selective antag

288 Pharmacophores were developed that served as a cornersto

289 gned using a merging strategy of both target pharmacophores, were explored using a versatile syntheti

290 oid alkyl side-chain represents an important pharmacophore, where genetic targeting of alkyl homologs

291 t and the linker moiety between chelator and pharmacophore, which influence the overall pharmacokinet

292 s with an extended confirmation and multiple pharmacophores while retaining solubility and oral bioav

293 proach, we demonstrate utility of a bivalent pharmacophore with dual activity as a mu/delta opioid ag

294 /3-negative-gating modulator, RA-2, as a new pharmacophore with nanomolar potency.

295 In the present study, we constructed a BACE1 pharmacophore with pepstatin and screened through molecu

296 Hybrid molecules are composed of two pharmacophores with different biological activities.

297 e inhibitors, they are considered to be poor pharmacophores with reduced activity in vivo.

298 armaceuticals possessing fluorine-containing pharmacophores with their targets.

299 ctamase inhibitors containing a boronic acid pharmacophore, with the goal of finding a potent inhibit

300 4 and C5 demonstrates that they create novel pharmacophores within each BC cell that is context speci